tiprankstipranks
Trending News
More News >
Affimed (AFMDQ)
OTHER OTC:AFMDQ
Advertisement

Affimed (AFMDQ) Price & Analysis

Compare
867 Followers

AFMDQ Stock Chart & Stats


Bulls Say, Bears Say

Bulls Say
Potential OpportunitiesUpcoming presentation at a major oncology meeting presents a potential opportunity to attract partners or funding.
Bears Say
Insolvency ProceedingsAffimed announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany.
Liquidity ConcernsThere is substantial doubt about the company's ability to continue as a going concern due to liquidity conditions.

AFMDQ FAQ

What was Affimed’s price range in the past 12 months?
Affimed lowest stock price was $0.01 and its highest was $4.20 in the past 12 months.
    What is Affimed’s market cap?
    Affimed’s market cap is $1.52K.
      When is Affimed’s upcoming earnings report date?
      Affimed’s upcoming earnings report date is Nov 18, 2025 which is in 69 days.
        How were Affimed’s earnings last quarter?
        Currently, no data Available
        Is Affimed overvalued?
        According to Wall Street analysts Affimed’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Affimed pay dividends?
          Affimed does not currently pay dividends.
          What is Affimed’s EPS estimate?
          Affimed’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Affimed have?
          Affimed has 15,227,463 shares outstanding.
            What happened to Affimed’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Affimed?
            Currently, no hedge funds are holding shares in AFMDQ

            Company Description

            Affimed

            Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

            Affimed (AFMDQ) Earnings & Revenues

            Similar Stocks
            Company
            Price & Change
            Follow
            Entero Therapeutics
            Evaxion Biotech
            Bolt Biotherapeutics
            GRI Bio
            SAB Biotherapeutics

            Ownership Overview

            1.41%9.37%89.22%
            Insiders
            9.37% Other Institutional Investors
            89.22% Public Companies and
            Individual Investors
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis